Skip to content

US · PROK · BIOTECHNOLOGY

ProKidney Corp. (PROK) intrinsic value and stock valuation

$1.04as of 2026-11-21 · Mkt cap 561.54M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ProKidney Corp. DCF and intrinsic value

InvestorsCraft values PROK with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PROK’s statements →

ProKidney Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Winston-Salem, NC 27103 prokidney.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$890K
20192025
Net income
-$-68.99M
20192025
Free cash flow
-$-135.31M
20192025
Total equity
$300.8M+98.1% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$890K$80K$0.00$0.00$0.00
Operating income-$-165.01M-$-183.68M-$-151.52M-$-153.01M-$-55.11M
Net income-$-68.99M-$-61.19M-$-35.47M-$-108.03M-$-55.15M
EPSd-$-515.08K-$-624.9K-$-574.79K-$-1.76M-$-1.73M
Operating cash flow-$-120.12M-$-126.35M-$-90.07M-$-77.09M-$-50.3M
Capital expenditure-$-15.2M-$-29.51M-$-34.2M-$-1.85M-$-5.19M
Free cash flow-$-135.31M-$-155.86M-$-124.27M-$-78.94M-$-55.49M
Total assets$335.6M$441.1M$420.6M$518M$40.3M
Total debt$4.04M$3.24M$4.41M$2.4M$1.33M
Net debt-$-104.5M-$-95.88M-$-56.24M-$-487.85M-$-19.22M
Total equity$300.8M$401.6M$391.3M$504.9M$26.9M
Cash and short-term investments$270M$358.3M$363M$490.3M$20.6M
Income statement
20252024202320222021
Revenue$890K$80K$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$890K$80K$0.00$0.00$0.00
Research and development expenses$114.1M$127.7M$106.7M$82.1M$46.3M
Selling, general and administrative expenses$51.8M$56.1M$44.8M$70.9M$8.86M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$165.9M$183.8M$151.5M$153M$55.1M
Cost and expenses$165.9M$183.8M$151.5M$153M$55.1M
Interest income$13.8M$19.8M$22.1M$5.98M$0.00
Interest expense$0.00$10K$10K$210K$0.00
Depreciation and amortization$6.58M$5.43M$3.85M$3.04M$1.98M
Ebitda-$-144.62M-$-158.49M-$-125.59M-$-143.99M-$-53.12M
Operating income-$-165.01M-$-183.68M-$-151.52M-$-153.01M-$-55.11M
Total other income/expenses, net$13.8M$19.7M$22.1M$5.77M$0.00
Income before tax-$-151.2M-$-163.93M-$-129.45M-$-147.24M-$-55.11M
Income tax expense$410K-$-600K$6M$900K$40K
Net income-$-68.99M-$-61.19M-$-35.47M-$-108.03M-$-55.15M
Weighted average shares outstanding$133.9M$97.9M$61.7M$61.5M$31.9M
Weighted average diluted shares outstanding$133.9M$97.9M$61.7M$61.5M$31.9M
Balance sheet
20252024202320222021
Cash and short-term investments$270M$358.3M$363M$490.3M$20.6M
Net receivables$1.13M$2.45M$1.38M$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$280.7M$395.9M$374.2M$504.7M$27.3M
Property, plant and equipment, net$54.9M$45.2M$46.4M$13.1M$12.6M
Goodwill and intangible assets$0.00$0.00$0.00$210K$430K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$54.9M$45.2M$46.4M$13.3M$13M
Total assets$335.6M$441.1M$420.6M$518M$40.3M
Accounts payable$940K$3.63M$5.1M$3.04M$2.83M
Short-term debt$1.07M$770K$800K$490K$270K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$30.7M$36.2M$25M$10.9M$12.3M
Long-term debt$2.96M$2.47M$3.61M$1.91M$1.07M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.04M$3.22M$4.18M$2.18M$1.07M
Capital lease obligations$4.04M$3.24M$4.41M$2.4M$1.33M
Total liabilities$34.8M$39.4M$29.2M$13.1M$13.4M
Common stock$30K$30K$20K$20K$188.4M
Retained earnings-$-1.27B-$-1.2B-$-1.14B-$-1.1B-$-161.51M
Accumulated other comprehensive income (loss)$60K$130K$130K$0.00$0.00
Total equity$300.8M$401.6M$391.3M$504.9M$26.9M
Total investments$161.5M$259.2M$302.3M$0.00$0.00
Total debt$4.04M$3.24M$4.41M$2.4M$1.33M
Net debt-$-104.5M-$-95.88M-$-56.24M-$-487.85M-$-19.22M
Cash flow statement
20252024202320222021
Net income-$-151.61M-$-163.34M-$-135.45M-$-148.13M-$-55.15M
Depreciation and amortization$6.58M$5.43M$3.85M$3.04M$1.98M
Stock-based compensation$25.3M$29.4M$30.9M$74.5M$700K
Change in working capital$1.28M$3.96M$16.7M-$-6.46M$2.16M
Accounts receivable$1.32M-$-1.07M-$-1.38M$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-5.92M$11.6M$11.6M$490K$10K
Net cash provided by operating activities-$-120.12M-$-126.35M-$-90.07M-$-77.09M-$-50.3M
Investments in property, plant and equipment-$-15.2M-$-29.51M-$-34.2M-$-1.85M-$-5.19M
Acquisitions, net$18.2M$0.00$0.00$110K$0.00
Net cash used for investing activities$104M$20.4M-$-329.98M-$-1.74M-$-5.19M
Common stock issued$25.6M$144.3M$0.00$6.05M$71.5M
Common stock repurchased$0.00$0.00-$-9.5M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$25.6M$144.4M-$-9.55M$548.5M$71.5M
Net change in cash$9.42M$38.5M-$-429.6M$469.7M$16M
Cash at end of period$108.5M$99.1M$60.7M$490.3M$20.6M
Operating cash flow-$-120.12M-$-126.35M-$-90.07M-$-77.09M-$-50.3M
Capital expenditure-$-15.2M-$-29.51M-$-34.2M-$-1.85M-$-5.19M
Free cash flow-$-135.31M-$-155.86M-$-124.27M-$-78.94M-$-55.49M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ProKidney Corp.

        ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.

        CEO
        Bruce Culleton
        Employees
        231
        Beta
        1.68

        Explore

        Frequently asked questions

        What is the intrinsic value of ProKidney Corp. (PROK)?

        InvestorsCraft does not currently publish an intrinsic value for PROK. How the IC value is calculated.

        Is PROK undervalued?

        InvestorsCraft does not publish an undervaluation signal for PROK at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.